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INTRODUCTION
Idiosyncratic drug induced liver injury (DILI) is a leading cause of acute liver failure in western countries ( 1, 2 ) . We recently demonstrated that ~60% of patients with bona fi de DILI in the US required hospitalization and that 10% of patients died or underwent liver transplantation within 6 months of DILI onset ( 2, 3 ) . Furthermore, 19% had evidence of liver injury 6 months aft er DILI onset defi ned by an elevated liver biochemistry level, abnormal liver imaging or histopathology ( 2 ) . Whether these patients will develop clinically signifi cant liver disease or simply experience slowly resolving liver injury during prolonged follow-up is unknown. Prior studies have suggested that continued administration of the suspect drug and presentation with an acute cholestatic liver injury profi le may result in a slower rate of laboratory Persistent Liver Biochemistry Abnormalities Are More Common in Older Patients and those With Cholestatic Drug Induced Liver Injury improvement and an increased risk of developing chronic liver disease (4) (5) (6) . However, the number of patients reported in these studies was limited and varying criteria were used to defi ne chronic liver injury (4) (5) (6) (7) (8) .
Th e aim of the current study is to describe the 2-year outcomes of consecutive adult DILI patients enrolled in the ongoing Drug Induced Liver Injury Network (DILIN) prospective study with evidence of ongoing liver injury 6 months aft er DILI onset. DILIN is a multicenter consortium sponsored by the National Institutes of Health that is conducting prospective studies focused on the etiology, risk factors, and natural history of DILI ( 8 ) . For the current study, patients with persistent liver injury (persisters) were defi ned by a serum AST or ALT >1.5×upper limit of normal (ULN) or an alkaline phosphatase >ULN at 12 months aft er DILI onset. Th ose not meeting these criteria were considered to have minimal to resolved liver injury (resolvers). Baseline and longitudinal parameters associated with persistent vs. resolving liver injury at 12 months aft er DILI onset were identifi ed. In addition to describing the evolution of laboratory parameters and liver histology, health related quality of life parameters were compared in the month 12 persisters and resolvers through 2 years of follow-up.
METHODS

Patient population
In all, 991 patients were enrolled in the DILIN prospective registry study from September 2004 through 31 July 2011. Th e research protocol was approved by the local institutional review boards and all participants provided written informed consent. Th e causal relationship between the liver injury episode and the implicated agent(s) were evaluated in a standardized fashion by the DILIN causality committee ( 8, 9 ). An overall DILIN causality score varying from 1 (Defi nite >95% likelihood), 2 (Very Likely 75-95% likelihood), 3 (Probable 50-74% likelihood), 4 (Possible 25-49% likelihood) to 5 (unlikely <25% likelihood) was assigned by consensus agreement of committee members ( 9 ) . In cases with 2 or more implicated drugs, an overall DILIN causality score was assigned and then an individual causality score was given for each suspect drug or herbal and dietary supplement. Of the 991 enrolled patients, 801 were adjudicated as defi nite, highly likely, or probable DILI. Of these 801 DILI patients, 143 were excluded from the analysis of early outcomes due to age<18 ( n =38), preexisting chronic hepatitis B or C infection ( n =28) or dropping out of the study before 6 month follow-up ( n =77). Of the remaining 660 patients, there were 62 patients who either died or underwent liver transplantation within 6 months of DILI onset. Th us, 598 adult DILIN patients had data available at baseline and 6 months aft er DILI onset for analysis of chronic DILI risk factors.
Of these 598 patients, 113 had chronic DILI at least 6 months aft er DILI onset defi ned by one or more of the following criteria: elevated serum AST, ALT, alkaline phosphatase or total bilirubin level, histological evidence of liver injury, or radiological evidence of liver disease (i.e., ascites on imaging) ( 3, 8 ) . Th ese 113 are the focus of this study, and per protocol, they were off ered follow-up through month 24 aft er DILI onset. Patients were categorized as either persisters or resolvers, based on the liver enzyme values at 12 months from DILI onset. Persisters were defi ned as serum AST or ALT >1.5×ULN or an alkaline phosphatase >ULN at 12 months from DILI onset. Resolvers did not meet these criteria and were considered to have minimal or no ongoing liver injury at 12 months aft er DILI onset.
Clinical data
A detailed medical and medication history was obtained at the baseline study visit and additional laboratory and radiological testing were performed to more fully characterize the DILI event and exclude competing etiologies of liver injury ( 2, 8 ) . Alcohol use was determined using the modifi ed Skinner instrument. Heavy alcohol use in the 5 years before DILI onset was defi ned as a mean consumption of >21 alcoholic beverages per week for men and >14 drinks per week for women. All enrolled patients were seen for a follow-up study visit at 6 months aft er initial enrollment. Th e subjects with ongoing liver injury at 6 months aft er DILI onset returned for additional follow-up study visits at 12 and 24 months aft er DILI onset. Severity of DILI injury was assessed on a 5 point scale used in the DILIN protocol with 1=asymptomatic to 5=Death/liver transplant ( 8 ) .
Assessment of symptoms
A 12 question Likert scale was completed by subjects at baseline and month 6, 12, and 24 study visits to assess for symptoms frequently reported in patients with liver disease including nausea, abdominal pain, fatigue, pruritus, pain over liver area, poor appetite, muscle aches, weakness, fevers and chills, rash, sadness, and overall feeling. Th e 10 point Likert scale varied from 1=not at all to 10=worse ever.
Health related quality of life
Th e SF-36 (version 1.0, Rand Corporation, Boston, MA) was completed at the baseline and months 6, 12, and 24 study visits ( 10 ) . Th e questionnaire is comprised of 8 scales: physical functioning, social functioning, role limitations due to physical health, role limitations due to emotional problems, mental health, vitality, bodily pain, and general health perceptions. Responses to questions in each scale are combined to create a score ranging between 0 (low) and 100 (high). In addition, these individual scale scores can be combined to create separate physical and mental health summary scores. Population norms were obtained from the SF-36 scoring manual that consists of 2,474 individuals with 47% between the ages of 18-44 and 57% female. Population norms were available only for the physical and mental health composite scores.
Liver histopathology
Available liver biopsies were reviewed by a single expert liver histopathologist (DEK). All samples were scored for multiple histological features as well as an overall pattern of liver injury ( 11 ) .
Statistics
Th e 113 patients with chronic DILI at 6 months aft er DILI onset were analyzed in this paper with available data through 10 March 2014 ( 2 ) . Th e two time scales of time from DILI onset and time from baseline visit were used for diff erent analyses due to the nature of data collection. For variables related to liver injury pattern over time (e.g., aminotransferase values), the time from DILI onset was used. For variables related to data collected at the specifi c study visits (e.g., symptom Likert scale and quality of life (QOL)), the time scale from baseline visit was used. Th e classifi cation of patients as persisters vs. resolvers was computed based on available laboratory values within 12 months of the DILI onset.
Non-parametric Wilcoxon test was used for comparison of the two groups for continuous variables, and χ 2 -test for categorical variables. Stepwise multivariate logistic regression analyses were used to identify independent factors at DILI onset or baseline study visit selected by clinical judgment for predicting month 12 persistent vs. resolved liver injury status. All model selection used an initial univariate analysis to screen potential candidates for multivariate modeling and only variables with<50% missing data were used. Variables with a univariate P value of 0.1 or less were considered including demographic variables (age, gender, race, weight, body mass index (BMI)) at baseline visit, signs and symptoms at DILI onset (except jaundice), medical histories, and various lab parameters at DILI onset. Th e model results are reported as odds ratio (OR) with 95% confi dence interval. A c-statistic was used to describe the fi t of the fi nal models.
SF-36 QOL scores were compared between the groups by linear regression models with adjustment for age and gender. All P values reported are two-sided and a level of 0.05 or less is considered statistically signifi cant. All data were analyzed by SAS 9.2 (SAS Institute, Cary, NC).
RESULTS
Patient population
Between September 2004 and August 2013, 113 of the 598 (18.8%) DILI patients had evidence of liver injury at 6 months aft er DILI onset. Th e manifestations of liver injury included serum AST, ALT, or alkaline phosphatase levels >baseline in 97 patients, liver function test 1.25 times of baseline on 2 occasions in 6, portal hypertension aft er 6 month from DILI onset in 8, radiological evidence of chronic liver injury in 23, histological evidence of chronic DILI in 6 and clinical evidence of chronic DILI in 36. Forty-three (38.1%) of the subjects met more than one criteria for chronic DILI. All of these patients were off ered further study visits at 12 and 24 months aft er their baseline study visit wherein standardized laboratory, radiological and clinical assessments were undertaken. Th e 99 patients with laboratory data obtained at 12 months from DILI onset form the basis of this report ( Figure 1 ). Of note the age, gender, DILIN severity score, and DILIN causality score were not signifi cantly diff erent in the 14 patients with missing data at 12 months from DILI onset compared with the 99 included in this analysis (data not shown).
Persisters and resolvers at 12 months after DILI onset
Seventy-four subjects had persistent laboratory evidence of liver injury at 12 months aft er DILI onset while 25 subjects were resolvers. Subjects with persistent liver injury had a similar BMI, gender, and racial distribution to those without persistent liver injury ( Table 1 ) . However, the month 12 persisters were significantly older (52.6 vs. 43.7 years, P =0.01) and were more likely to have a history of heart disease (35.1 vs. 4%, P <0.01). Interestingly, those with persistent liver injury had a signifi cantly higher initial and peak serum alkaline phosphatase level and a lower initial and peak serum ALT level. Not surprisingly, the proportion of subjects with cholestatic liver injury at presentation was higher in the persisters vs. resolvers (54.1 vs. 20%, P <0.01). However, the initial and peak total bilirubin, albumin, and international normalized ratio levels in the two groups were similar. Th e frequency of antinuclear antibodies and smooth muscle antibodies were similar in the two groups at their baseline study visit. On multivariate analysis, subject age and higher serum alkaline phosphatase levels at DILI onset were independent predictors of persistent liver injury at 12 months aft er DILI onset (C-statistic=0.74 95% confi dence interval: 0.63: 0.85, See Supplementary Table 1 online) .
Th e suspect drugs implicated in the month 12 persisters and resolvers were similar with antimicrobial antibiotics being the most commonly implicated agents in both groups ( Supplementary Table 2 ). Th e mean causality scores were also similar in the two groups as were the DILIN severity scores ( Table 1 ). In addition, the frequency of prednisone and ursodeoxycholic acid use during follow-up was similar in the two patient groups.
Evolution of liver biochemistries over time
Th e month 12 persisters had signifi cantly higher serum alkaline phosphatase levels at DILI onset compared with those who resolved their liver injury at month 12. Although the serum alkaline phosphatase, total bilirubin and aminotransferase levels tended to improve in both groups over time, the persisters had signifi cantly higher alkaline phosphatase levels at months 6, 12, and 24 compared with the resolvers ( P <0.01). In addition, although the serum AST and ALT levels were signifi cantly lower at DILI onset in the persisters, they were subsequently higher than the resolvers at the month 6, 12, and 24 study visits ( Table 2 ) . Th e proportion of month 12 persisters and resolvers with serum ALT >3×ULN at DILI onset, month, 6, 12, and 24 were 73%, 27%, 27%, and 21% and 88%, 8%, 0%, and 5%, respectively. Repeat anti-nuclear antibodies and SmAb levels were not obtained at the month 6, 12, and 24 study visits.
SF-36 scores at baseline and follow-up study visits
Th e age and gender adjusted SF-36 scores of the two groups of patients are presented in Figure 2 . At the baseline DILIN study visit, the persisters had signifi cantly lower Physical Component Summary (PCS) scores (35 vs. 42.4, P =0.003), physical function scores (51.9 vs. 77 P =0.001), and General Health (GH) scores (56.2 vs. 66.3, P =0.044) ( Figure 2a ) . However, the Mental Health summary (MCS) scores and other subscale scores were similar. Th e PCS remained signifi cantly lower in the month 12 persisters vs. resolvers at month 6 and 12 and were also lower at the month 24 study visit ( Figure 2b ) . Furthermore, the Physical Function scores in the month 12 persisters were consistently lower compared with LIVER Two-Year Outcomes in DILI resolvers during follow-up as well ( Figure 2c ). Th ese data indicate that the subjects with laboratory evidence of persistent liver injury 12 months aft er DILI onset have signifi cantly poorer QOL at initial enrollment that persists for 2 years compared with those with resolving liver injury.
Hepatitis symptoms at baseline and follow-up visits
Eleven clinical symptoms associated with acute hepatitis were recorded from all patients at the baseline, month 6, month 12, and 24 study visits ( Supplementary Table 3 ). Subjects with laboratory evidence of persistent liver injury at 12 months had similar clinical symptoms at presentation to those who eventually resolved both at DILI onset and throughout follow-up.
Histopathologic evolution of DILI over time
A liver biopsy was not required for enrollment into the DILIN study and protocolized biopsies were not obtained during followup. Nonetheless, liver biopsy slides obtained by local physicians for clinical management purposes were available for review in 17 patients of whom 12 also had one or two biopsies during their acute DILI episode. For the 3 patients with 2 acute DILI biopsies, data from the second biopsy was utilized in Table 3 . Th e mean age of these 17 subjects was 48.3 years and 70% were female. Amongst the 12 patients with follow-up biopsies, the median BMI was 25.6 kg/m 2 (range: 19.9 to 31.6 kg/m 2 ), 33% were diabetic, and the liver biochemistries available before initiating the suspect drug were all normal. In addition, none of these patients had known chronic liver disease before DILI onset. Th e liver injury was hepatocellular, mixed, and cholestatic at DILI onset in fi ve, two, and fi ve patients respectively. At the time of the second biopsy, the laboratory injury had shift ed to two hepatocellular, two mixed and eight cholestatic. Before DILI onset, seven patients reported no alcohol consumption and fi ve reported <10 drinks/ month. Th e median time from DILI onset to their initial liver biopsy was 22 days and 446 days to their additional biopsy done during follow-up. Th ere were 14 individual agents implicated in these cases including 3 patients with nitrofurantoin and 2 with azithromycin induced hepatotoxicity. Th e most common pattern of liver injury observed on follow-up biopsy was chronic cholestasis in nine patients (53%). Th ree patients each had either chronic hepatitis or steatohepatitis patterns. Of note, only 1 patient had evidence of a ductular reaction on their initial biopsy while seven demonstrated evidence of bile duct loss during follow-up, including the only patient classifi ed in blinded review as a non-infl ammatory zonal cholestatic liver injury during follow-up. Th is 73-year-old woman had presented with an acute cholestatic liver injury attributed to lansoprazole that was associated with extensive granulomas and cholestasis on her fi rst biopsy that evolved into a prominent zone 3 cholestasis with no signifi cant infl ammation or fi brosis despite a persistently elevated alkaline phosphatase level. In the 12 patients Figure 1 . Overview of Study population. Amongst the 598 patients enrolled in DILIN between 9/04 and 7/11, 113 patients met protocol defi ned criteria for ongoing liver injury at 6 months after DILI onset. Amongst those patients, the 99 subjects with laboratory data available at month 12 after DILI onset were categorized as persisters ( n =75) if they had abnormal liver biochemistries or resolvers ( n =24). DILI, drug induced liver injury; DILIN, Drug Induced Liver Injury Network.
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with more than one biopsy, 8 demonstrated fi brosis progression of at least one Ishak stage over a mean time interval of 397 days. Th e only patient to show regression of fi brosis had DILI due to tamoxifen. Th is patient had three biopsies, demonstrating progression of steatohepatitis features and fi brosis between the fi rst and second biopsies while she was receiving tamoxifen. However, following the discontinuation of tamoxifen, the third biopsy demonstrated regression of fi brosis as well as reduction in ballooning injury and steatosis. Th e eight patients with fi brosis progression all had cholestatic liver injury and included all six of the patients with paired biopsies who showed bile duct loss. Of note, none of the six patients with evidence of bile duct loss on their follow-up 
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liver biopsy demonstrated evidence of bile duct loss on their initial biopsy ( Table 3 ). An informative case of the histopathological evolution of persistent DILI is seen in Supplementary Figure 1 . A 51-year-old Caucasian male presented with jaundice, pruritus, and acholic stools aft er taking metoclopramide for 1 month for refractory gastroesophageal refl ux disease. His initial ALT was 779 IU/l, alkaline phosphatase 859 IU/l, and total bilirubin 6.9 mg/dl and his bilirubin peaked 3 weeks later at 20.4 mg/dl. A liver biopsy obtained 89 days aft er DILI onset when his alkaline phosphatase was 1150 IU/l demonstrated mild portal infi ltrates with periductal infl ammation but no fi brosis. With persistent fatigue at ~16 months aft er DILI onset and an alkaline phosphatase of 659 IU/l and total bilirubin of 0.7 mg/dl, he underwent a second liver biopsy that demonstrated marked chronic cholestatic changes with ductular reaction and ductopenia. Th e patient continued to have ongoing liver injury at his month 24 study visit with symptoms of fatigue and a serum ALT of 240 IU/l, alkaline phosphatase of 497 IU/l, and total bilirubin of 0.5 mg/dl.
DISCUSSION
Prior studies have demonstrated that 5-10% of patients with idiosyncratic DILI will die or undergo liver transplantation within 6 months of DILI onset ( 1-3 ) . In addition to characterizing early adverse outcomes, a primary aim of the DILIN prospective study is to better determine the long-term clinical outcomes in DILI patients with ongoing liver injury at 6 months or more aft er DILI onset ( 2,3 ). As a result, all eligible subjects had a standardized battery of liver biochemistries drawn and also had symptoms, medications, and interval medical history recorded at each follow-up study visit through 2 years. Early on, we noted that some of the patients completely normalized their labs during follow-up while others continued to have persistent laboratory abnormalities. Persistent liver injury was defi ned in this study as a patient with a serum AST or ALT >1.5×ULN or an elevated serum alkaline phosphatase level at 12 months aft er DILI onset ( 12, 13 ) . We feel that the objective, laboratory criteria we selected to defi ne persistent liver injury at 12 months aft er DILI onset are reasonable since all of the patients had an episode of well-documented acute liver injury at enrollment ( Table 1 ) . Furthermore, serum AST and ALT levels were normal in 88 of the 99 patients included in this analysis who had labs available before starting the suspect medication. Using this defi nition, nearly 75% of the current cohort had laboratory evidence of ongoing liver injury at 12 months aft er DILI onset while the remaining 25% had resolved their liver injury as evidenced by normalization of laboratory results. Of note, the majority of subjects were not jaundiced at month 6 and this proportion remained low during follow-up. However, the mean serum AST, ALT, and alk phos levels remained signifi cantly higher in the month 12 persisters at month 24 compared with the resolvers ( Table 2 ) .
To determine if the month 12 persisters had more severe symptoms or functional impairment from their liver disease, we compared the self-reported symptom scores and SF-36 scores of the two patient groups at multiple time points. Th e clinical symptoms reported by both groups of patients were generally mild at their baseline study visit which took place a mean of 93 (range: 12-342) days aft er DILI onset in the persisters and 45 (range: 5-287) days aft er DILI onset in the resolvers. Furthermore, no signifi cant differences in clinical symptoms were noted in the two groups during follow-up ( Supplementary Table 3 ). However, clinically significant diff erences were noted in multiple SF-36 subscale and summary scores at the baseline study visit in the two groups of patients ( Figure 2a ). In particular, the physical function and role physical scores were markedly lower as was the PCS. Th e persistence of Table 1 ) . Th e observed association of persistent liver injury with increasing patient age is not surprising. Studies of acute liver failure patients have demonstrated that older subjects are more likely to die or experience greater morbidity presumably due to impaired hepatic regeneration ( 14 ) . Older age is a strong determinant of developing chronic hepatitis C virus infection aft er initial exposure and older patients demonstrate greater evidence of hepatic infl ammation and fi brosis progression during follow-up ( 15, 16 ) . Older donor livers also do not fare as well in living and deceased donor liver transplantation and aging promotes the development of hepatic infl ammation and liver cell injury in animal models of hepatic steatosis (17) (18) (19) . Th ese data cumulatively suggest that older individuals are at greater risk of developing severe and potentially progressive liver injury following an acute DILI episode compared with younger individuals. Th e observation that subjects with cholestatic liver injury at DILI onset are at greater risk of having persistent liver injury during prolonged follow-up is perhaps one of our most important fi ndings. Some drugs associated with cholestatic liver injury early on can lead to severe prolonged cholestasis and even ductopenia these diff erences during 2 years of follow-up suggest that subjects destined to have persistent DILI truly have a poorer QOL and do not feel as well from DILI onset through 2 years of follow-up compared with those who will resolve their liver injury. It also suggests that our defi nition of persistent liver injury may have discerning value of clinical importance. Whether persisters go on to develop cirrhosis, portal hypertension, or symptoms of subclinical hepatic encephalopathy with more prolonged follow-up is an intriguing but unknown possibility ( 6 ) .
Another aim of the current study was to identify baseline features associated with persistent liver injury that may be of use to clinicians in counseling future patients. Of note, there was no association between the type of suspect medication or duration of use with persistent DILI. However, the mean duration of suspect medication use in the 113 patients who formed the basis of this report was signifi cantly longer than the 485 patients with self-limited DILI ( 2 ) . Furthermore, gender, BMI, immunoallergic features (i.e., eosinophilia, rash, and fever) and autoantibodies at DILI onset were also not associated with persistent liver injury. However, older patient age and higher serum alkaline phosphatase levels at presentation were both signifi cant and independent risk factors for The PCS scores improved in both groups of patients but signifi cant differences remained in the month 6, month 12, and month 24 PCS scores between the subjects with persistent and resolved liver injury. ( c ) The physical function scores of the month 12 persisters remained signifi cantly lower than the resolvers at the baseline, month 6, month 12, and month 24 study visits. BP, bodily pain; GH, general health; MCS, mental health summary score; MH, mental health; PF, physical function; RE, role emotional; RP, role physical; SF, social functioning; PCS, physical summary score; VT, vitality.
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during follow-up in a minority of affl icted patients. (20) (21) (22) In particular, some patients with severe acute cholestatic drug reactions may go on to develop protracted liver disease with repeated hospitalizations and even development of cirrhosis ( 6 ) . Furthermore, subjects with a cholestatic DILI episode in one study were more likely to develop chronic liver injury and a small proportion of these patients also developed progressive liver fi brosis ( 5 ). However, the mechanism(s) behind this association remains unclear. In primary biliary cirrhosis, there is evidence that the Canals of Hering along with the small bile ducts, are targets of an immunemediated attack ( 23, 24 ) . Th is disrupts the normal relationship of hepatocytes to bile ducts, stimulating a ductular reaction that can lead to subsequent hepatic fi brosis ( 25 ) . Among our eight cases with fi brosis progression, six showed duct loss and four showed ductular reaction, while none of the four cases without fi brosis progression had either duct loss or ductular reaction ( Table 3 ) . Unfortunately, immunostains for keratin 19 and keratin 7 were not available to further explore these cases. Th erefore, we speculate that the mechanism(s) of fi brosis involved in our chronic cholestatic DILI cases may be similar to those involved in other immune-mediated chronic cholestatic liver diseases but additional studies of a larger group of consecutive DILI patients are needed. Th e patients with clinically driven follow-up liver biopsies available for review in our cohort provided us a unique opportunity to explore the pathological evolution of chronic liver injury from DILI. Although only a few patients had follow-up biopsies, in those that did, the biopsies mainly showed chronic injury patterns with varying severity of hepatic fi brosis and just over half showed chronic cholestasis. Th is histological pattern of injury is in keeping with the persistent cholestatic laboratory injury profi le and is unlikely to be the result of pre-existing liver disease. In support of this, none of the patients in Table 3 reported a known history of pre-existing liver disease, the liver biochemistries were normal in subjects with data available before starting the suspect drug and the median BMI in these 12 patients was only 25.6 kg/m 2 . In patients with a baseline and a follow-up biopsy, fi brosis progression was seen in two-thirds of cases, even though the time between biopsies was relatively short. Since liver fi brosis staging may be underestimated in smaller liver biopsies, we reviewed the size of the tissue samples ( Table 3 ) and found that the majority of biopsies had an adequate number of portal triads to allow for the accurate staging of fi brosis ( 26 ) . Interestingly, all six patients with duct loss on follow-up did not have evidence of early duct loss on their initial biopsy but had a mixed or cholestatic lab profi le at initial presentation and at the time of follow-up biopsy. In addition, all 6 of these patients with ductopenia during follow-up also had fi brosis progression and may be at risk for the development of a biliary cirrhosis. Th e only patient that showed clear regression of fi brosis had steatohepatitis due to tamoxifen.
Th ere are several limitations of our study. Firstly, only a minority of patients had liver biopsy performed during follow-up and these were for clinical indications which may have led to selection bias. In addition, the biopsies were not obtained at a uniform time aft er DILI onset. Furthermore, we cannot completely exclude the possibility that some of the persisters may have had hepatic 
